ijms-logo

Journal Browser

Journal Browser

New Therapeutic Strategies for Lung Cancer: An Update

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 3595

Special Issue Editor


E-Mail Website
Guest Editor
Department of BioHealthcare, Hwasung Medi-Science University, Hwaseong-si 18274, Gyeonggi-do, Republic of Korea
Interests: molecular mechanism; tumor microenvironment; epithelial-to-mesenchymal transition (EMT); post-translational modification (PTM); autophagy; potential therapeutic approaches; preclinical mouse models for cancers; breast cancer; liver cancer; lung cancer; pancreatic cancer; cancer progression and metastasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Lung cancer is the leading cancer cause of death worldwide in recent decades, mainly divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung metastasis is regulated by several elements, such as the interactions among various types of signaling in the lung cancer microenvironment and epithelial–mesenchymal transition (EMT). At the same time, there have been significant advances in lung cancer therapies, such as chemotherapy, targeted therapy, radiotherapy, and miRNA-based therapy immunotherapy.

This Special Issue on “New Therapeutic Strategies for Lung Cancer: An Update” aims to provide value for future investigations and promising therapeutic clues. It is also focused on the discovery of molecular insights and potential therapeutic approaches. Authors are invited to submit original research and topical review articles related to these topics.

Dr. Mi Kyung Park
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • lung metastasis
  • epithelial–mesenchymal transition (EMT)
  • lung cancer therapeutics
  • mouse models of lung cancer
  • tumor microenvironment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

27 pages, 1722 KiB  
Review
Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent
by Lu Yu, Ho Lee, Seung Bae Rho, Mi Kyung Park and Chang Hoon Lee
Int. J. Mol. Sci. 2023, 24(7), 6712; https://doi.org/10.3390/ijms24076712 - 4 Apr 2023
Cited by 2 | Viewed by 3212
Abstract
Ethacrynic acid (ECA) is a diuretic that inhibits Na-K-2Cl cotransporter (NKCC2) present in the thick ascending loop of Henle and muculo dens and is clinically used for the treatment of edema caused by excessive body fluid. However, its clinical use is limited due [...] Read more.
Ethacrynic acid (ECA) is a diuretic that inhibits Na-K-2Cl cotransporter (NKCC2) present in the thick ascending loop of Henle and muculo dens and is clinically used for the treatment of edema caused by excessive body fluid. However, its clinical use is limited due to its low bioavailability and side effects, such as liver damage and hearing loss at high doses. Despite this, ECA has recently emerged as a potential anticancer agent through the approach of drug repositioning, with a novel mechanism of action. ECA has been shown to regulate cancer hallmark processes such as proliferation, apoptosis, migration and invasion, angiogenesis, inflammation, energy metabolism, and the increase of inhibitory growth factors through various mechanisms. Additionally, ECA has been used as a scaffold for synthesizing a new material, and various derivatives have been synthesized. This review explores the potential of ECA and its derivatives as anticancer agents, both alone and in combination with adjuvants, by examining their effects on ten hallmarks of cancer and neuronal contribution to cancer. Furthermore, we investigated the trend of synthesis research of a series of ECA derivatives to improve the bioavailability of ECA. This review highlights the importance of ECA research and its potential to provide a cost-effective alternative to new drug discovery and development for cancer treatment. Full article
(This article belongs to the Special Issue New Therapeutic Strategies for Lung Cancer: An Update)
Show Figures

Figure 1

Back to TopTop